{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:58:58Z","timestamp":1780761538536,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Colorado Lung Cancer SPORE","award":["P50CA058187"],"award-info":[{"award-number":["P50CA058187"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.lungcan.2018.07.001","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:31:28Z","timestamp":1532046688000},"page":"260-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Antibody drug conjugates in thoracic malignancies"],"prefix":"10.1016","volume":"124","author":[{"given":"Jose M.","family":"Pacheco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-3213","authenticated-orcid":false,"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"February (4)","key":"10.1016\/j.lungcan.2018.07.001_bib0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates\u2014an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"April (4)","key":"10.1016\/j.lungcan.2018.07.001_bib0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody-drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"October (2)","key":"10.1016\/j.lungcan.2018.07.001_bib0015","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","article-title":"Cell killing by antibody-drug conjugates","volume":"255","author":"Kovtun","year":"2007","journal-title":"Cancer Lett."},{"issue":"February (2)","key":"10.1016\/j.lungcan.2018.07.001_bib0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(24)38014-0","article-title":"Active efflux of CPT-11 and its metabolites in human KB-derived cell lines","volume":"288","author":"Chu","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"March (3)","key":"10.1016\/j.lungcan.2018.07.001_bib0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00280-001-0393-3","article-title":"Factors influencing the cellular accumulation of SN-38 and camptothecin","volume":"49","author":"Cummings","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"June (5)","key":"10.1016\/j.lungcan.2018.07.001_bib0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001813-200106000-00003","article-title":"Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells","volume":"12","author":"Yamamoto","year":"2001","journal-title":"Anticancer Drugs"},{"issue":"August (24)","key":"10.1016\/j.lungcan.2018.07.001_bib0035","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of advanced non-small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecanccw","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0040","series-title":"Presented at the San Antonio Breast Cancer Symposium","article-title":"Sacituzumab govitecan (IMMU-132), an anti-trop-2-SN-38 antibody-drug conjugate, as \u2265 3rd-line therapeutic option for patients with relapsed\/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results","author":"Bardia","year":"2017"},{"issue":"October (19)","key":"10.1016\/j.lungcan.2018.07.001_bib0045","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of small cell lung Cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.14694\/EdBook_AM.2012.32.109","article-title":"Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody","author":"Burris","year":"2012","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"May(9)","key":"10.1016\/j.lungcan.2018.07.001_bib0055","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"issue":"December (2)","key":"10.1016\/j.lungcan.2018.07.001_bib0060","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"February (2)","key":"10.1016\/j.lungcan.2018.07.001_bib0065","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A phase II study of trastuzumab emtansine in HER2-Positive non-small cell lung Cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"November (21)","key":"10.1016\/j.lungcan.2018.07.001_bib0070","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2018.07.001_bib0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8509","article-title":"Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)","volume":"35","author":"Stinchcombe","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/JCO.2017.35.31_suppl.35","article-title":"Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: results from a phase II basket trial","author":"Li","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0085","series-title":"Abstract OA 14.05. Presented at the IASLC 18th World Conference on Lung Cancer","article-title":"Phase 2 basket trial of ado-trastuzumab emtansine in patients with HER2 mutant or amplified lung cancers","author":"Li","year":"2017"},{"issue":"November (19)","key":"10.1016\/j.lungcan.2018.07.001_bib0090","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for Her2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"February (4","key":"10.1016\/j.lungcan.2018.07.001_bib0095","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0100","series-title":"Abstract MA 02.10. Presented at the IASLC 18th World Conference on Lung Cancer","article-title":"Phase I study of telisotuzumab vedotin (ABBV-399) as monotherapy and in combination with erlotinib in NSCLC","author":"Goldman","year":"2017"},{"issue":"August (302)","key":"10.1016\/j.lungcan.2018.07.001_bib0105","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"January (1)","key":"10.1016\/j.lungcan.2018.07.001_bib0110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8507","article-title":"Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-Expressing, \u2265 3rd line small cell lung cancer: results from the phase 2 TRINITY study","volume":"36","author":"Carbone","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0120","unstructured":"https:\/\/news.abbvie.com\/news\/abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-rova-t-for-third-line-treatment-patients-with-dll3-expressing-relapsedrefractory-small-cell-lung-cancer.htm. (Accessed 24 March 2018)."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0125","series-title":"Abstract OA 02.01. Presented at the 18th World Conference on Lung Cancer","article-title":"Randomized phase 2 study of anetumab ravtansine in malignant pleural mesothelioma","author":"Kindler","year":"2017"},{"issue":"December (34)","key":"10.1016\/j.lungcan.2018.07.001_bib0130","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"January (1)","key":"10.1016\/j.lungcan.2018.07.001_bib0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/bc900315y","article-title":"Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates","volume":"21","author":"Erickson","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"June (6)","key":"10.1016\/j.lungcan.2018.07.001_bib0140","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogenous target expression favored by a bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"June (6)","key":"10.1016\/j.lungcan.2018.07.001_bib0145","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-16-0021","article-title":"A new triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells","volume":"15","author":"Singh","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"October (2)","key":"10.1016\/j.lungcan.2018.07.001_bib0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","article-title":"Novel antibody therapeutics targeting mesothelin in solid tumors","volume":"3","author":"Zhao","year":"2016","journal-title":"Clin. Cancer Drugs"},{"issue":"15","key":"10.1016\/j.lungcan.2018.07.001_bib0155","article-title":"Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR)","volume":"34","author":"Blumenschein","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"June (3)","key":"10.1016\/j.lungcan.2018.07.001_bib0160","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10637-016-0336-9","article-title":"Phase I study of IMGN901, a CD-56 targeting antibody-drug conjugate, in patients with CD56-positive solid tumors","volume":"34","author":"Shah","year":"2016","journal-title":"Invest. New Drugs"},{"issue":"Junuary (16)","key":"10.1016\/j.lungcan.2018.07.001_bib0165","first-page":"23","article-title":"Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma","author":"Fossella","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"January (1)","key":"10.1016\/j.lungcan.2018.07.001_bib0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cllc.2016.09.002","article-title":"Phase 1\/2 study of the CD56-targetting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin\/etoposide in small-cell lung cancer patients with extensive-stage disease","volume":"18","author":"Socinski","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"August (4)","key":"10.1016\/j.lungcan.2018.07.001_bib0175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620712443076","article-title":"Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"3","author":"Vaklavas","year":"2012","journal-title":"Ther. Adv. Hematol."},{"issue":"March (3)","key":"10.1016\/j.lungcan.2018.07.001_bib0180","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-14-0972","article-title":"CD30 is a potential therapeutic target in malignant mesothelioma","volume":"14","author":"Dabir","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"November (5)","key":"10.1016\/j.lungcan.2018.07.001_bib0185","article-title":"Brentuximab vedotin in patients with CD30+ mesothelioma","volume":"90","author":"Jalal","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"March (5)","key":"10.1016\/j.lungcan.2018.07.001_bib0190","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"issue":"Junuary","key":"10.1016\/j.lungcan.2018.07.001_bib0195","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.lungcan.2017.03.019","article-title":"CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies","volume":"108","author":"Remon","year":"2017","journal-title":"Lung Cancer"},{"issue":"January (1)","key":"10.1016\/j.lungcan.2018.07.001_bib0200","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/0008-5472.CAN-13-1436","article-title":"A reevaluation of CD22 expression in human lung cancer","volume":"74","author":"Pop","year":"2014","journal-title":"Cancer Res."},{"issue":"November (21)","key":"10.1016\/j.lungcan.2018.07.001_bib0205","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1158\/0008-5472.CAN-12-0173","article-title":"CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy","volume":"72","author":"Tuscano","year":"2012","journal-title":"Cancer Res."},{"issue":"April (8)","key":"10.1016\/j.lungcan.2018.07.001_bib0210","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1158\/0008-5472.CAN-06-3914","article-title":"Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species","volume":"67","author":"Alexandre","year":"2007","journal-title":"Cancer Res."},{"issue":"October (1)","key":"10.1016\/j.lungcan.2018.07.001_bib0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2006.05.020","article-title":"A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma","volume":"54","author":"Ross","year":"2006","journal-title":"Lung Cancer"},{"issue":"May(10)","key":"10.1016\/j.lungcan.2018.07.001_bib0220","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-13-2775","article-title":"A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma","volume":"74","author":"Chen","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0225","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5565","article-title":"PF06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7) in patients (pts) with advanced solid tumors: results of a phase I dose escalation and expansion study","volume":"36","author":"Sachdev","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.2501","article-title":"Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts","volume":"36","author":"Iwata","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"August (9944)","key":"10.1016\/j.lungcan.2018.07.001_bib0235","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramicirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"issue":"November (315)","key":"10.1016\/j.lungcan.2018.07.001_bib0240","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"February","key":"10.1016\/j.lungcan.2018.07.001_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0250","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.2574","article-title":"Clinical pharmacology assessment of PF-06647020(PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors","volume":"36","author":"Xuan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.07.001_bib0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.108","article-title":"Single agent activity of DS-8201a, a HER-2 targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors","volume":"35","author":"Doi","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218304604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218304604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T22:26:43Z","timestamp":1751754403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218304604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":51,"alternative-id":["S0169500218304604"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.07.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody drug conjugates in thoracic malignancies","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}